BRCA1 and breast carcinoma: While in the context of breast cancer, it is classically used to treat cases of triple-negative disease, emerging evidence supports the experimental and clinical relevance of cisplatin in ER+ breast cancer models, particularly in tamoxifen-resistant or BRCA1-mutant contexts [24].